Onmel is a drug owned by Sebela Ireland Ltd. It is protected by 4 US drug patents filed in 2013. Out of these, 1 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 03, 2028. Details of Onmel's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8486456 | Itraconazole compositions with improved bioavailability |
Oct, 2028
(3 years from now) | Active |
| US8591948 | Antifungal compositions with improved bioavailability |
May, 2017
(8 years ago) |
Expired
|
| US6509038 | Antifungal compositions with improved bioavailability |
May, 2017
(8 years ago) |
Expired
|
| US7081255 | Antifungal compositions with improved bioavailability |
May, 2017
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Onmel's patents.
Latest Legal Activities on Onmel's Patents
Given below is the list of recent legal activities going on the following patents of Onmel.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 May, 2021 | US8591948 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Dec, 2020 | US8486456 |
| Expire Patent Critical | 27 Aug, 2018 | US7081255 |
| Maintenance Fee Reminder Mailed Critical | 05 Mar, 2018 | US7081255 |
| Post Issue Communication - Certificate of Correction | 30 Apr, 2014 | US8486456 |
| Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 20 Mar, 2014 | US8486456 |
| Mail-Record a Petition Decision of Granted to Issue Patent in Name of the Assignee | 20 Mar, 2014 | US8486456 |
| Petition Entered | 20 Mar, 2014 | US8486456 |
| Post Issue Communication - Certificate of Correction Denied | 12 Dec, 2013 | US8486456 |
| Patent Issue Date Used in PTA Calculation Critical | 26 Nov, 2013 | US8591948 |
FDA has granted several exclusivities to Onmel. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Onmel, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Onmel.
Exclusivity Information
Onmel holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Onmel's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2013 |
US patents provide insights into the exclusivity only within the United States, but Onmel is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Onmel's family patents as well as insights into ongoing legal events on those patents.
Onmel's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Onmel's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 03, 2028 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Onmel Generic API suppliers:
Itraconazole is the generic name for the brand Onmel. 13 different companies have already filed for the generic of Onmel, with Amneal Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Onmel's generic
Alternative Brands for Onmel
Onmel which is used for treating onychomycosis of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes., has several other brand drugs using the same active ingredient (Itraconazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Itraconazole, Onmel's active ingredient. Check the complete list of approved generic manufacturers for Onmel
About Onmel
Onmel is a drug owned by Sebela Ireland Ltd. It is used for treating onychomycosis of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes. Onmel uses Itraconazole as an active ingredient. Onmel was launched by Sebela Ireland Ltd in 2010.
Approval Date:
Onmel was approved by FDA for market use on 29 April, 2010.
Active Ingredient:
Onmel uses Itraconazole as the active ingredient. Check out other Drugs and Companies using Itraconazole ingredient
Treatment:
Onmel is used for treating onychomycosis of the toenail caused by Trichophyton rubrum or Trichophyton mentagrophytes.
Dosage:
Onmel is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 200MG | TABLET | Discontinued | ORAL |